Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-09, Stock:ABBV, The news for the past five days is as follows:
2018-03-02: NEWS1: Dow Drops 771 Points This Week as Tariffs, Powell Rough Up Stocks.NEWS2: Biogen, AbbVie Pull Multiple Sclerosis Drug On Inflammation Reports.NEWS3: 3 Top Dividend Stocks to Buy Right Now.NEWS4: 3 Top Dividend Stocks to Buy Right Now.NEWS5: [$$] Biogen and Abbvie Take Multiple Sclerosis Drug Off Market.NEWS6: 3 Top Dividend Stocks to Buy Right Now.NEWS7: Biogen, AbbVie pull multiple sclerosis drug from market amid safety concerns.NEWS8: Biogen, AbbVie to take multiple sclerosis drug off global market.NEWS9: Notable ETF Inflow Detected - MTUM, BA, ABBV, AMAT.NEWS10: Notable ETF Inflow Detected - MTUM, BA, ABBV, AMAT.NEWS11: Nasdaq, S&P 500 Turn Positive But Dow Closes Lower - U.S. Commentary.NEWS12: Nasdaq, S&P 500 Turn Positive But Dow Closes Lower - U.S. Commentary.NEWS13: Multiple Sclerosis Relapse Drug Is Pulled After Patient Safety Concerns.NEWS14: Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta.NEWS15: 8 Dividend Payouts That Are Soaring on Tax Cuts.NEWS16: Major Averages Turn Mixed After Seeing Initial Weakness - U.S. Commentary.NEWS17: Major Averages Turn Mixed After Seeing Initial Weakness - U.S. Commentary.NEWS18: Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta.NEWS19: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis.NEWS20: Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts.NEWS21: Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts.
2018-03-05: NEWS1: Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut.NEWS2: Here's My Top Stock to Buy in March.NEWS3: Here's My Top Stock to Buy in March.NEWS4: Here&apos;s My Top Stock to Buy in March.NEWS5: Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month.
2018-03-06: NEWS1: 10 Companies Making Huge Stock Buybacks in 2018.NEWS2: 10 Companies Making Huge Stock Buybacks in 2018.NEWS3: Profit From Share Buyback Boom With These ETFs.NEWS4: Profit From Share Buyback Boom With These ETFs.NEWS5: Gilead Sciences’ Valuation in March 2018.NEWS6: Bristol-Myers Squibb’s Eliquis and Orencia Saw Solid Growth in 2017.NEWS7: Gilead Announces Positive Data on New HIV Therapy Biktarvy.NEWS8: Gilead Announces Positive Data on New HIV Therapy Biktarvy.
2018-03-07: NEWS1: FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs.NEWS2: Biogen, AbbVie's Zinbryta, yanked from market, connected to three U.S. cases of brain inflammation.NEWS3: Zinbrynta Now Connected To Brain Inflammation.NEWS4: Zinbrynta Now Connected To Brain Inflammation.NEWS5: Why Gilead Sciences’ Harvoni Lost Market Share in 4Q17.NEWS6: Gilead Sciences’ HCV Products: Lower Revenues in 4Q17.NEWS7: Johnson & Johnson’s Pharmaceutical Segment in 4Q17.NEWS8: Europe's medicines regulator calls for recall of Biogen, AbbVie multiple sclerosis drug.
2018-03-08: NEWS1: M&A, Innovation & New Drugs to Drive Pharma Stocks.NEWS2: Want to be a Buy and Hold Investor? 3 Strategies.NEWS3: Want to be a Buy and Hold Investor? 3 Strategies.NEWS4: Want to be a Buy and Hold Investor? 3 Strategies.NEWS5: Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta.NEWS6: Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta.NEWS7: Multimillion-dollar drug yanked from market connected to dangerous brain inflammation cases in U.S..NEWS8: Multimillion-dollar drug yanked from market connected to dangerous brain inflammation cases in U.S..NEWS9: Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta.NEWS10: Key Updates on BMY’s Reyataz and Hepatitis C Franchise.NEWS11: Validea John Neff Strategy Daily Upgrade Report - 3/8/2018.NEWS12: Validea John Neff Strategy Daily Upgrade Report - 3/8/2018.

Answer: Rise